tiprankstipranks
Trending News
More News >

OncoSil Medical Reports Record Growth in Q3 FY25

Story Highlights
OncoSil Medical Reports Record Growth in Q3 FY25

Confident Investing Starts Here:

OncoSil Medical Ltd ( (AU:OSL) ) has issued an announcement.

OncoSil Medical Ltd reported record quarterly dose sales for Q3 FY25, driven by increased clinical adoption of the OncoSil™ device. The company saw a 233% increase in dose sales compared to the previous year, contributing to an 83% rise in year-to-date sales and a 135% increase in year-to-date revenues. This growth highlights the company’s successful market penetration and strategic advancements, including receiving MDR approval and expanding its presence in German hospitals. The financial results indicate a promising outlook for future revenue growth as sales figures are expected to be more fully realized in upcoming quarters.

More about OncoSil Medical Ltd

OncoSil Medical Ltd is a medical device company specializing in localized treatments for patients with unresectable locally advanced pancreatic cancer. The company focuses on the development and clinical adoption of the OncoSil™ device, targeting key geographic markets to enhance its market presence.

Technical Sentiment Signal: Buy

Current Market Cap: A$18.43M

See more data about OSL stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App